Renal Fibrosis

Renal fibrosis is a progressive pathological process characterized by the excessive accumulation of extracellular matrix (ECM) components, including collagen types I, III, and IV, fibronectin, and proteoglycans, within the renal parenchyma. This process leads to the destruction of functional nephrons, architectural distortion, and ultimately end-stage renal disease (ESRD). In veterinary medicine, renal fibrosis is a common final pathway of various chronic kidney diseases (CKD) in dogs and cats, regardless of the initial etiology. It is a dynamic process involving inflammation, tubular atrophy, interstitial expansion, and glomerulosclerosis. The severity of fibrosis correlates strongly with the decline in glomerular filtration rate (GFR) and the progression of clinical signs. Renal fibrosis can be classified based on the primary compartment affected: tubulointerstitial fibrosis (most common), glomerulosclerosis, and perivascular fibrosis. The condition is typically irreversible, and therapeutic strategies aim to slow its progression rather than reverse established fibrosis.

The etiology of renal fibrosis is multifactorial, with numerous primary insults leading to a common pathway of fibrogenesis. In dogs and cats, common causes include: 1) Chronic kidney disease (CKD) of unknown origin, often associated with aging, particularly in cats where tubulointerstitial nephritis is prevalent. 2) Glomerulonephritis (immune-complex mediated), secondary to chronic infections (e.g., bacterial endocarditis, brucellosis, leishmaniasis), neoplasia, or autoimmune diseases. 3) Congenital and hereditary nephropathies, such as renal dysplasia, polycystic kidney disease (PKD) in Persian cats, and familial nephropathies in breeds like the Samoyed (X-linked hereditary nephritis) and Bull Terrier (hereditary nephritis). 4) Toxins and drugs: chronic exposure to nephrotoxins such as aminoglycosides, non-steroidal anti-inflammatory drugs (NSAIDs), heavy metals (lead, cadmium), and certain plants (lilies in cats). 5) Infectious agents: bacterial pyelonephritis (e.g., E. coli), leptospirosis, and viral infections (feline infectious peritonitis, FIV, FeLV). 6) Ischemic injury: prolonged hypotension, renal artery stenosis, or thromboembolism leading to chronic hypoxia and subsequent fibrosis. 7) Obstructive uropathy: chronic ureteral or urethral obstruction causing hydronephrosis and progressive renal damage. 8) Endocrine disorders: hyperadrenocorticism (Cushing's syndrome) and diabetes mellitus can contribute to glomerular hypertension and fibrosis. 9) Idiopathic causes: many cases of CKD in cats have no identifiable primary etiology, suggesting a multifactorial pathogenesis involving genetic predisposition, diet, and environmental factors.

Renal fibrosis is a common finding in aged dogs and cats. In cats, CKD is highly prevalent, affecting approximately 30-40% of cats over 10 years of age, with tubulointerstitial fibrosis being the predominant histopathological lesion. In dogs, the prevalence of CKD is lower, estimated at 0.5-1% of the general population, but increases with age. Certain breeds are predisposed to specific nephropathies that lead to fibrosis: for example, Bull Terriers and English Cocker Spaniels have hereditary nephritis; Samoyeds and Doberman Pinschers are prone to X-linked hereditary nephritis; Persian cats are predisposed to PKD; and Bernese Mountain Dogs have an increased risk of glomerulonephritis. There is no strong sex predilection, but some immune-mediated glomerulonephritides may be more common in males. Geographic variations exist, with infectious causes like leptospirosis being more prevalent in certain regions. The incidence of renal fibrosis is expected to rise with increasing lifespan of pets, emphasizing the need for early detection and management.

The pathophysiology of renal fibrosis is a complex cascade involving cellular injury, inflammation, and aberrant repair. Initially, an insult (toxic, ischemic, immune, or infectious) damages tubular epithelial cells, glomerular cells, and endothelial cells. Injured tubular cells undergo apoptosis or necrosis, releasing damage-associated molecular patterns (DAMPs) that activate the innate immune system. Resident macrophages and infiltrating monocytes produce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and chemokines (MCP-1, RANTES), recruiting more inflammatory cells. Transforming growth factor-beta (TGF-β) is the master pro-fibrotic cytokine, released by macrophages, tubular cells, and myofibroblasts. TGF-β stimulates the transdifferentiation of fibroblasts into myofibroblasts, which express α-smooth muscle actin and produce excessive ECM. Additionally, epithelial-to-mesenchymal transition (EMT) of tubular epithelial cells contributes to the myofibroblast pool. The accumulation of ECM in the interstitium leads to tubular atrophy, peritubular capillary loss, and hypoxia, further perpetuating injury. Glomerulosclerosis results from mesangial cell proliferation and ECM deposition in the glomeruli. The renin-angiotensin-aldosterone system (RAAS) is activated, with angiotensin II promoting fibrosis via TGF-β induction and direct effects on fibroblasts. The loss of nephrons leads to compensatory hyperfiltration in remaining nephrons, causing glomerular hypertension and proteinuria, which itself is nephrotoxic. Eventually, the kidney becomes shrunken, fibrotic, and non-functional.

Predisposing factors for renal fibrosis include: 1) Age: older animals have reduced renal reserve and increased susceptibility to insults. 2) Genetic predisposition: certain breeds have inherited defects in collagen IV (e.g., Samoyed hereditary nephritis) or cilia function (PKD). 3) Chronic proteinuria: persistent proteinuria is both a marker and a promoter of renal damage, leading to tubular overload and interstitial inflammation. 4) Hypertension: systemic and intraglomerular hypertension cause endothelial injury and glomerulosclerosis. 5) Hyperphosphatemia: elevated serum phosphorus levels are associated with progression of CKD and fibrosis. 6) Anemia: chronic hypoxia may exacerbate renal injury. 7) Obesity: associated with systemic inflammation and glomerular hyperfiltration. 8) Diet: high protein diets may increase glomerular pressure, while high phosphorus diets contribute to mineral imbalance. 9) Concurrent diseases: diabetes mellitus, hyperadrenocorticism, and chronic infections increase the risk. 10) Medications: long-term use of nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) can initiate injury. 11) Environmental toxins: exposure to heavy metals or certain plants (lilies in cats) can cause acute kidney injury that progresses to fibrosis.

Clinical signs of renal fibrosis are those of chronic kidney disease and are often insidious in onset. In early stages, animals may be asymptomatic or show mild polyuria and polydipsia (PU/PD). As fibrosis progresses, signs become more pronounced: 1) Early stage (IRIS Stage 1-2): subtle PU/PD, mild weight loss, poor hair coat, and occasional vomiting. 2) Moderate stage (IRIS Stage 3): more obvious PU/PD, decreased appetite, lethargy, intermittent vomiting, and halitosis. 3) Advanced stage (IRIS Stage 4): severe lethargy, anorexia, persistent vomiting, diarrhea, oral ulcers (uremic stomatitis), weakness, muscle wasting, and dehydration. 4) Terminal stage: uremic encephalopathy (seizures, coma), severe metabolic acidosis, hypothermia, and death. Physical examination may reveal small, irregular kidneys on palpation (in chronic cases), pale mucous membranes (anemia), oral ulcerations, and a uremic odor to the breath. Hypertension may be present, leading to retinal changes (hypertensive retinopathy) and cardiac murmurs. In cats, cervical ventroflexion due to hypokalemia may be observed.

Differential diagnoses for renal fibrosis (as a cause of CKD) include: 1) Acute kidney injury (AKI): distinguished by sudden onset, larger kidneys, and potentially reversible if treated early. 2) Chronic pyelonephritis: history of recurrent urinary tract infections, bacteriuria, and renal pelvic dilation on imaging. 3) Renal lymphoma (especially in cats): may present with renomegaly, but histopathology is diagnostic. 4) Renal amyloidosis: often associated with proteinuria and underlying chronic inflammation; Congo red staining is positive. 5) Polycystic kidney disease: multiple cysts visible on ultrasound, often in predisposed breeds. 6) Hydronephrosis: due to ureteral obstruction, with marked pelvic dilation. 7) Renal neoplasia (e.g., renal adenocarcinoma): usually unilateral, with mass effect. 8) Chronic interstitial nephritis (non-specific): histologically similar, but fibrosis is the hallmark. 9) Diabetic nephropathy: history of diabetes mellitus, with glomerulosclerosis. 10) Hypercalcemic nephropathy: history of hypercalcemia (e.g., hyperparathyroidism, malignancy), with calcium deposition in the kidney.

The diagnostic approach to renal fibrosis involves: 1) History and physical examination: signalment, onset of signs, PU/PD, palpation of kidneys. 2) Baseline blood work: CBC, serum biochemistry (BUN, creatinine, phosphorus, calcium, potassium, sodium, chloride, albumin, globulins), and symmetric dimethylarginine (SDMA) as a more sensitive marker of GFR. 3) Urinalysis: urine specific gravity (USG), dipstick, sediment examination, and urine protein-to-creatinine ratio (UPC). 4) Blood pressure measurement: Doppler or oscillometric to detect hypertension. 5) Imaging: abdominal radiography to assess kidney size and shape; ultrasonography to evaluate echogenicity, corticomedullary distinction, and presence of cysts or masses. 6) Further tests: if glomerular disease is suspected, consider serology for infectious agents (e.g., leptospirosis, leishmaniasis), antinuclear antibody (ANA) for autoimmune disease, and urine culture. 7) Renal biopsy: indicated when the cause is unclear, or to guide therapy (e.g., distinguishing glomerulonephritis from amyloidosis). Biopsy can be performed percutaneously under ultrasound guidance or surgically. Histopathology confirms fibrosis and identifies the underlying etiology. 8) Staging: based on IRIS guidelines, using serum creatinine and SDMA levels, with substaging for proteinuria and hypertension.

Laboratory findings in renal fibrosis reflect decreased renal function and its consequences: 1) Hematology: non-regenerative anemia due to decreased erythropoietin production; normocytic, normochromic anemia. 2) Serum biochemistry: elevated BUN and creatinine (azotemia), hyperphosphatemia, metabolic acidosis (decreased bicarbonate), hyperkalemia (especially in oliguric or anuric stages), hypokalemia (in cats with chronic PU/PD), and possibly hypercalcemia or hypocalcemia. 3) SDMA: elevated SDMA is an early indicator of decreased GFR, often preceding creatinine elevation. 4) Urinalysis: isosthenuria (USG < 1.030 in dogs, < 1.035 in cats), proteinuria (UPC > 0.5 in dogs, > 0.4 in cats), and inactive sediment (no significant cells or casts). 5) Blood gas analysis: metabolic acidosis with low pH and bicarbonate. 6) Biomarkers: NT-proBNP may be elevated due to cardiac strain from hypertension or volume overload; troponin I may be elevated if myocardial damage. 7) Endocrine assays: if hyperadrenocorticism or diabetes is suspected, ACTH stimulation test or fructosamine levels may be indicated. 8) Serology/PCR: for infectious causes like leptospirosis (microscopic agglutination test, PCR) or feline retroviruses (FeLV/FIV).

Imaging findings in renal fibrosis: 1) Radiography: kidneys may be small and irregular in chronic cases; in advanced fibrosis, they may be difficult to visualize due to mineralization. 2) Ultrasonography: kidneys often show increased echogenicity of the cortex, loss of corticomedullary distinction, and reduced renal size. Doppler ultrasound may show decreased renal blood flow. 3) Computed tomography (CT): can provide detailed assessment of renal volume and perfusion, but is rarely needed for diagnosis. 4) Magnetic resonance imaging (MRI): not routinely used, but can detect fibrosis via diffusion-weighted imaging. 5) Endoscopy: not applicable. 6) Fluoroscopy: not used. 7) Echocardiography: may be indicated to assess cardiac changes secondary to hypertension or fluid overload.

Cytology and histopathology are essential for definitive diagnosis and etiologic classification. 1) Fine needle aspirate (FNA) of the kidney: may show non-specific changes such as tubular epithelial cells, inflammatory cells, and occasionally neoplastic cells if a tumor is present. FNA is not reliable for diagnosing fibrosis. 2) Renal biopsy: histopathology reveals interstitial fibrosis (Masson's trichrome stain highlights collagen), tubular atrophy, glomerulosclerosis, and variable inflammatory infiltrate (lymphocytes, plasma cells, macrophages). Special stains: Congo red for amyloidosis, Jones methenamine silver for basement membrane changes, and immunofluorescence for immune complex deposition (IgG, IgM, C3). Electron microscopy can identify specific glomerular lesions. The degree of fibrosis can be graded (mild, moderate, severe) and correlates with prognosis.

Treatment of renal fibrosis focuses on slowing progression, managing complications, and supportive care. There is no specific anti-fibrotic therapy approved in veterinary medicine, but several strategies are used: 1) Dietary management: renal diets low in protein, phosphorus, and sodium, and supplemented with omega-3 fatty acids (EPA/DHA). Protein restriction is moderate (e.g., 2.5-3.5 g/kg/day for dogs, 3.5-4.5 g/kg/day for cats) to reduce uremic toxins. Phosphorus restriction is crucial; if diet alone is insufficient, phosphate binders (e.g., aluminum hydroxide, calcium carbonate) are used. 2) RAAS inhibition: ACE inhibitors (e.g., enalapril 0.5 mg/kg PO q12-24h, benazepril 0.25-0.5 mg/kg PO q24h) or angiotensin receptor blockers (e.g., telmisartan 1 mg/kg PO q24h) are used to reduce proteinuria and glomerular hypertension. 3) Management of hypertension: amlodipine (0.1-0.25 mg/kg PO q24h) is the first-line agent; ACE inhibitors may also help. 4) Treatment of proteinuria: ACE inhibitors or telmisartan are indicated if UPC > 0.5 in dogs or > 0.4 in cats. 5) Management of anemia: erythropoietin (e.g., darbepoetin alfa 1 μg/kg SC once weekly) or blood transfusion in severe cases. 6) Management of metabolic acidosis: sodium bicarbonate (8-12 mg/kg PO q8-12h) or potassium citrate. 7) Management of hyperkalemia: dietary restriction, and if severe, insulin/glucose therapy or calcium gluconate. 8) Management of hypokalemia (common in cats): potassium supplementation (e.g., potassium gluconate 2-4 mEq/kg/day PO). 9) Anti-fibrotic agents: experimental, but some evidence supports the use of pirfenidone (not approved in veterinary medicine) or tranilast. 10) Supportive care: antiemetics (e.g., maropitant 1 mg/kg SC q24h), appetite stimulants (e.g., mirtazapine 3.75 mg/cat PO q48h), and fluid therapy for dehydration. 11) Dialysis: hemodialysis or peritoneal dialysis may be considered for acute exacerbations or end-stage disease, but is not widely available. 12) Renal transplantation: an option for cats with end-stage CKD, but limited by availability and cost.

The prognosis for renal fibrosis is generally guarded to poor, as the condition is progressive and irreversible. The rate of progression varies depending on the underlying cause, stage at diagnosis, and response to therapy. Median survival times for cats with CKD (IRIS Stage 2-4) range from 1-3 years, with Stage 4 having a median survival of less than 6 months. In dogs, survival times are variable; those with proteinuria and hypertension have a worse prognosis. Negative prognostic indicators include: advanced IRIS stage, severe proteinuria (UPC > 2.0), hypertension, hyperphosphatemia, anemia, and poor body condition. Early intervention and strict management can slow progression and improve quality of life. Some animals may remain stable for months to years with appropriate therapy.

Follow-up for renal fibrosis involves regular monitoring to assess disease progression and adjust therapy. Recommended schedule: 1) Recheck every 1-3 months for stable patients, more frequently if unstable. 2) At each visit: body weight, body condition score, blood pressure, serum biochemistry (BUN, creatinine, SDMA, phosphorus, potassium, bicarbonate), and UPC. 3) Urinalysis to monitor USG and sediment. 4) CBC to monitor anemia. 5) Imaging (ultrasound) every 6-12 months to assess kidney size and structure. 6) Adjust medications based on laboratory results: phosphate binders dose based on serum phosphorus; ACE inhibitors dose based on blood pressure and UPC; potassium supplementation based on serum potassium. 7) Monitor for complications: uremic crises, urinary tract infections, and progression to end-stage disease. 8) Educate owners on signs of decompensation and when to seek emergency care.

Pearls: 1) SDMA is more sensitive than creatinine for early detection of decreased GFR; use it to diagnose CKD earlier. 2) Proteinuria is a key modifiable risk factor; always measure UPC and treat if elevated. 3) Hypertension is common in CKD; control blood pressure to slow progression. 4) In cats, hypokalemia can cause cervical ventroflexion; supplement potassium. 5) Renal diets are the cornerstone of management; start early. 6) Use phosphate binders with meals to maximize efficacy. 7) Consider renal biopsy if the cause is unclear, as specific therapy may be available (e.g., immunosuppression for immune-mediated glomerulonephritis). Pitfalls: 1) Do not use NSAIDs in animals with renal disease; they can worsen injury. 2) Avoid over-restriction of protein, which can lead to malnutrition. 3) Do not use ACE inhibitors if the animal is dehydrated or hypotensive; correct volume status first. 4) Do not ignore hyperphosphatemia; it is a strong driver of progression. 5) Do not rely solely on creatinine to monitor progression; SDMA and UPC are more informative. 6) Do not forget to screen for concurrent diseases like hyperthyroidism in cats or diabetes mellitus in dogs.

Based on Plumb's Veterinary Drug Handbook, the following protocols are commonly used: 1) ACE inhibitors: Enalapril (dogs: 0.5 mg/kg PO q12-24h; cats: 0.25-0.5 mg/kg PO q24h) or Benazepril (dogs: 0.25-0.5 mg/kg PO q24h; cats: 0.25-0.5 mg/kg PO q24h). Monitor blood pressure and renal function within 1-2 weeks of initiation. 2) Angiotensin receptor blocker: Telmisartan (dogs: 1 mg/kg PO q24h; cats: 1-2 mg/kg PO q24h). 3) Antihypertensive: Amlodipine (dogs: 0.1-0.25 mg/kg PO q24h; cats: 0.1-0.25 mg/kg PO q24h). 4) Phosphate binders: Aluminum hydroxide (dogs: 30-100 mg/kg/day PO divided with meals; cats: 30-100 mg/kg/day PO divided with meals) or Calcium carbonate (dogs: 90 mg/kg/day PO divided with meals; cats: 90 mg/kg/day PO divided with meals). 5) Potassium supplementation: Potassium gluconate (dogs: 0.5-1 mEq/kg/day PO; cats: 2-4 mEq/cat/day PO). 6) Sodium bicarbonate (dogs: 8-12 mg/kg PO q8-12h; cats: 8-12 mg/kg PO q8-12h) to correct acidosis. 7) Erythropoietin: Darbepoetin alfa (dogs: 1 μg/kg SC once weekly; cats: 1 μg/kg SC once weekly) or Epoetin alfa (dogs: 100 U/kg SC three times weekly; cats: 100 U/kg SC three times weekly). 8) Antiemetics: Maropitant (dogs: 1 mg/kg SC q24h; cats: 1 mg/kg SC q24h) or Ondansetron (dogs: 0.5-1 mg/kg IV q12h; cats: 0.5-1 mg/kg IV q12h). 9) Appetite stimulant: Mirtazapine (cats: 3.75 mg/cat PO q48h; dogs: 0.5-1 mg/kg PO q24h). 10) Gastroprotectants: Famotidine (dogs: 0.5-1 mg/kg PO q12-24h; cats: 0.5-1 mg/kg PO q12-24h) or Omeprazole (dogs: 0.5-1 mg/kg PO q24h; cats: 0.5-1 mg/kg PO q24h). 11) For immune-mediated glomerulonephritis: Prednisone (dogs: 1-2 mg/kg PO q24h, then taper) and Mycophenolate (dogs: 10-20 mg/kg PO q12h) or Cyclosporine (dogs: 5-10 mg/kg PO q24h). 12) For infectious causes: appropriate antibiotics (e.g., doxycycline for leptospirosis, 5 mg/kg PO q12h). Always adjust dosages for renal impairment and monitor for adverse effects.

Key evidence in veterinary nephrology: 1) IRIS (International Renal Interest Society) staging guidelines provide a standardized approach to CKD diagnosis and management, emphasizing SDMA and proteinuria. 2) The ACVIM consensus statement on proteinuria (2005) recommends ACE inhibitors for proteinuric CKD. 3) Studies have shown that telmisartan is as effective as benazepril in reducing proteinuria in cats (e.g., a randomized controlled trial by Sent et al., 2015). 4) The role of diet is supported by a landmark study by Ross et al. (2006) showing that renal diets slow progression in cats with CKD. 5) Omega-3 fatty acids have been shown to reduce inflammation and fibrosis in experimental models (e.g., Brown et al., 1998). 6) The use of SDMA has been validated as an early biomarker (e.g., Hall et al., 2014). 7) Management of hypertension is based on studies like that by Jepson et al. (2007) showing amlodipine is effective. 8) For anemia, studies have shown that darbepoetin is safe and effective in cats (e.g., Chalhoub et al., 2012). 9) There is ongoing research into anti-fibrotic agents, but none are currently approved for veterinary use. 10) The overall prognosis and survival data are summarized in studies like that by Boyd et al. (2008) in cats and by O'Neill et al. (2013) in dogs.